Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion

Summary

The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary atherosclerosis.

Timeline

Start

2019-08-30

Primary completion

2021-08-27

Completion

2023-02-24

Drugs

Indications